IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval

(MedPage Today) — The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.
The tablets are indicated…

Source link : https://www.medpagetoday.com/nephrology/generalnephrology/114955

Author :

Publish date : 2025-04-03 16:51:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval

Study: Treat Adult-Onset Still’s Disease With Biologics

Artificial sweetener boosts hunger cues in the brain

Related Posts

Adjuvant Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous SCC

Neurodevelopmental and Psychiatric Disorders in Duchenne Muscular Dystrophy

Best quantum ‘transistor’ yet could lead to more accurate computers

Methotrexate for Osteoarthritis: Dead End After All?

UK Pharmacies Struggle with Severe Creon Shortage

From ’10/10′ Pain to ’10/10′ Healthcare

Adjuvant Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous SCC

Neurodevelopmental and Psychiatric Disorders in Duchenne Muscular Dystrophy

Best quantum ‘transistor’ yet could lead to more accurate computers

Methotrexate for Osteoarthritis: Dead End After All?

UK Pharmacies Struggle with Severe Creon Shortage

From ’10/10′ Pain to ’10/10′ Healthcare

New Preoperative Regimen Gets a Win in Pancreatic Cancer

Deep Cuts Erode Public Health’s Foundation, End Progress, Threaten Worse to Come

Categories

Archives